Unicycive Therapeutics, Inc. (UNCY) Stock Price & Growth Analysis - Tweevest

New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out

Unicycive Therapeutics, Inc.

UNCY

NASDAQ

Unprofitable

Unprofitable

35M

Biotechnology

Next Earning date - 12 Nov 2024

35M

Biotechnology

Next Earning date - 12 Nov 2024

0.37USD

-0.01 ( -1.66%)

Relative Strenght

10

Volume Buzz

-35%

Earning Acce

No

Dist 52w H.

79%

Quote Panel

Updated October 7, 2024

1W -1.01 % 1M 0.86 % 3M -20.49 % 1Y -54.26 %

Key Metrics

Market Cap
35.26M
Shares Outstanding
94.36M
Share in Float
84.53M
Dividende
0

Earning Date
12 Nov 2024
Price Target
0.3737
Average Volume
2.45M
Beta
2.348

Range
0.202-1.818
Industry
Biotechnology
Website
https://www.unicycive.com
Sector
Healthcare

Fundamentals

N/A

P/E Ratio

Nanx

P/S Ratio

-0.95x

P/B Ratio

-3.1

Debt/Equity

10788.2%

Net Margin

$-0.4

EPS

How UNCY compares to sector?

P/E Ratio

Relative Strength

UNCY

Sector

loading...

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Forecast

$33M

NaN%

2025-Revenue

$0.34

-523%

2025-EPS

$7M

188%

2025-EBITDA

Analyst rating

No Data Available

Last analyst upgrade/downgrade

Piper Sandler

initialise

Previous: Not converted

2024-04-04

Now: Overweight

Earnings Growth

YoY

Current

Estimates

Q3.22

N/A

-0.37
vs -0.37

Q4.22

N/A

-0.35
vs -0.17

Q1.23

N/A

-0.29
vs -0.24

Q2.23

N/A

-0.29
vs -0.24

Q3.23

N/A

-0.13
vs -0.37

Q4.23

N/A

-0.16
vs -0.35

Q1.24

N/A

-0.27
vs -0.29

Q2.24

N/A

-0.15
vs -0.29

Q3.24

N/A

-0.15
vs -0.13

Q4.24

N/A

-0.14
vs -0.16

Sales Growth

YoY

Current

Estimates

Q2.22

NA

NA vs NA

Q3.22

NA

951K vs NA

Q4.22

NA

NA vs NA

Q1.23

NA

675K vs NA

Q2.23

NA

NA vs NA

Q3.23

-100%

NA vs 951K

Q4.23

NA

-271000.00 vs NA

Q1.24

-100%

NA vs 675K

Q2.24

NA

NA vs NA

Q4.24

+3790%

10M vs -271000

Return on Equity

QoQ

Q3.22

-120%

-1.20
vs -0.37

Q4.22

+1144%

11.44
vs -1.20

Q1.23

-239%

-2.39
vs 11.44

Q2.23

-56%

-0.56
vs -2.39

Q3.23

-128%

-1.28
vs -0.56

Q4.23

+205%

2.05
vs -1.28

Q1.24

+86%

0.86
vs 2.05

Q2.24

-26%

-0.26
vs 0.86

Institutionnal Ownership

QoQ

Q3.22

11

11
vs 14

-21%

Q4.22

9

9
vs 11

-18%

Q1.23

13

13
vs 9

44%

Q2.23

15

15
vs 13

15%

Q3.23

16

16
vs 15

7%

Q4.23

16

16
vs 16

NA

Q1.24

23

23
vs 16

44%

Q2.24

24

24
vs 23

4%

Earnings Growth

Latest News

UNCY

globenewswire.com

7 hours ago

Unicycive Therapeutics to Participate in a Fireside Chat at the Virtual Lytham Partners Fall 2024 Investor Conference on October 1, 2024

UNCY

globenewswire.com

7 hours ago

Unicycive Therapeutics to Present at the Virtual Life Sciences Investor Forum on September 19, 2024

UNCY

globenewswire.com

7 hours ago

Unicycive Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

UNCY

globenewswire.com

7 hours ago

Unicycive Therapeutics Announces Submission of the New Drug Application (NDA) to the U.S. FDA for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis

UNCY

globenewswire.com

7 hours ago

Unicycive Therapeutics to Present Three Posters at the American Society of Nephrology (ASN) Kidney Week 2024

UNCY

globenewswire.com

7 hours ago

Unicycive Announces Second Quarter 2024 Financial Results and Provides Business Update

New Feature Coming Soon, Stay Tuned!

Shape

Shape